vs
Amneal Pharmaceuticals, Inc.（AMRX）与TRINET GROUP, INC.（TNET）财务数据对比。点击上方公司名可切换其他公司
TRINET GROUP, INC.的季度营收约是Amneal Pharmaceuticals, Inc.的1.5倍（$1.2B vs $814.3M），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs -2.2%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $43.0M），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs -0.6%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
TriNet Group, Inc.是一家面向中小企业的专业雇主组织，总部位于加州都柏林，服务员工规模在3至2500人之间的各类机构。可提供薪资管理、健康福利管理服务，还能为客户提供劳动法规合规、风险降低相关咨询，可作为外包人力资源部门为企业分担人事相关事务。
AMRX vs TNET — 直观对比
营收规模更大
TNET
是对方的1.5倍
$814.3M
营收增速更快
AMRX
高出13.7%
-2.2%
自由现金流更多
AMRX
多$65.5M
$43.0M
两年增速更快
AMRX
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.2B |
| 净利润 | $35.1M | — |
| 毛利率 | 36.5% | — |
| 营业利润率 | 13.8% | 0.1% |
| 净利率 | 4.3% | — |
| 营收同比 | 11.5% | -2.2% |
| 净利润同比 | 212.9% | — |
| 每股收益（稀释后） | $0.10 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXTNET
| Q4 25 | $814.3M | $1.2B | ||
| Q3 25 | $784.5M | $1.2B | ||
| Q2 25 | $724.5M | $1.2B | ||
| Q1 25 | $695.4M | $1.3B | ||
| Q4 24 | $730.5M | $1.3B | ||
| Q3 24 | $702.5M | $1.2B | ||
| Q2 24 | $701.8M | $1.2B | ||
| Q1 24 | $659.2M | $1.3B |
净利润AMRXTNET
| Q4 25 | $35.1M | — | ||
| Q3 25 | $2.4M | $34.0M | ||
| Q2 25 | $22.4M | $37.0M | ||
| Q1 25 | $12.2M | $85.0M | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-156.0K | $45.0M | ||
| Q2 24 | $6.0M | $60.0M | ||
| Q1 24 | $-91.6M | $91.0M |
毛利率AMRXTNET
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 36.1% | — |
营业利润率AMRXTNET
| Q4 25 | 13.8% | 0.1% | ||
| Q3 25 | 9.0% | 4.1% | ||
| Q2 25 | 15.4% | 4.1% | ||
| Q1 25 | 14.4% | 8.9% | ||
| Q4 24 | 10.4% | -2.9% | ||
| Q3 24 | 12.6% | 4.7% | ||
| Q2 24 | 13.6% | 6.5% | ||
| Q1 24 | -1.6% | 9.7% |
净利率AMRXTNET
| Q4 25 | 4.3% | — | ||
| Q3 25 | 0.3% | 2.8% | ||
| Q2 25 | 3.1% | 3.0% | ||
| Q1 25 | 1.8% | 6.6% | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | -0.0% | 3.6% | ||
| Q2 24 | 0.9% | 4.9% | ||
| Q1 24 | -13.9% | 7.2% |
每股收益（稀释后）AMRXTNET
| Q4 25 | $0.10 | $0.02 | ||
| Q3 25 | $0.01 | $0.70 | ||
| Q2 25 | $0.07 | $0.77 | ||
| Q1 25 | $0.04 | $1.71 | ||
| Q4 24 | $-0.10 | $-0.44 | ||
| Q3 24 | $0.00 | $0.89 | ||
| Q2 24 | $0.02 | $1.20 | ||
| Q1 24 | $-0.30 | $1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $287.0M |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $54.0M |
| 总资产 | $3.7B | $3.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXTNET
| Q4 25 | $282.0M | $287.0M | ||
| Q3 25 | $201.2M | $321.0M | ||
| Q2 25 | $71.5M | $407.0M | ||
| Q1 25 | $59.2M | $349.0M | ||
| Q4 24 | $110.6M | $360.0M | ||
| Q3 24 | $74.0M | $301.0M | ||
| Q2 24 | $43.8M | $249.0M | ||
| Q1 24 | $46.5M | $383.0M |
总债务AMRXTNET
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益AMRXTNET
| Q4 25 | $-70.8M | $54.0M | ||
| Q3 25 | $-109.5M | $110.0M | ||
| Q2 25 | $-112.1M | $107.0M | ||
| Q1 25 | $-131.7M | $63.0M | ||
| Q4 24 | $-109.3M | $69.0M | ||
| Q3 24 | $-93.4M | $129.0M | ||
| Q2 24 | $-57.5M | $100.0M | ||
| Q1 24 | $-63.7M | $143.0M |
总资产AMRXTNET
| Q4 25 | $3.7B | $3.8B | ||
| Q3 25 | $3.6B | $3.4B | ||
| Q2 25 | $3.4B | $3.7B | ||
| Q1 25 | $3.4B | $3.8B | ||
| Q4 24 | $3.5B | $4.1B | ||
| Q3 24 | $3.5B | $3.7B | ||
| Q2 24 | $3.5B | $3.7B | ||
| Q1 24 | $3.5B | $4.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $61.0M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $43.0M |
| 自由现金流率自由现金流/营收 | 13.3% | 3.4% |
| 资本支出强度资本支出/营收 | 2.7% | 1.4% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | $234.0M |
8季度趋势，按日历期对齐
经营现金流AMRXTNET
| Q4 25 | $130.3M | $61.0M | ||
| Q3 25 | $118.5M | $72.0M | ||
| Q2 25 | $83.8M | $75.0M | ||
| Q1 25 | $7.4M | $95.0M | ||
| Q4 24 | $118.1M | $65.0M | ||
| Q3 24 | $141.8M | $84.0M | ||
| Q2 24 | $39.7M | $39.0M | ||
| Q1 24 | $-4.4M | $91.0M |
自由现金流AMRXTNET
| Q4 25 | $108.5M | $43.0M | ||
| Q3 25 | $106.2M | $55.0M | ||
| Q2 25 | $61.0M | $57.0M | ||
| Q1 25 | $-5.8M | $79.0M | ||
| Q4 24 | $102.9M | $47.0M | ||
| Q3 24 | $124.8M | $59.0M | ||
| Q2 24 | $29.0M | $22.0M | ||
| Q1 24 | $-13.6M | $73.0M |
自由现金流率AMRXTNET
| Q4 25 | 13.3% | 3.4% | ||
| Q3 25 | 13.5% | 4.5% | ||
| Q2 25 | 8.4% | 4.6% | ||
| Q1 25 | -0.8% | 6.1% | ||
| Q4 24 | 14.1% | 3.7% | ||
| Q3 24 | 17.8% | 4.8% | ||
| Q2 24 | 4.1% | 1.8% | ||
| Q1 24 | -2.1% | 5.8% |
资本支出强度AMRXTNET
| Q4 25 | 2.7% | 1.4% | ||
| Q3 25 | 1.6% | 1.4% | ||
| Q2 25 | 3.2% | 1.5% | ||
| Q1 25 | 1.9% | 1.2% | ||
| Q4 24 | 2.1% | 1.4% | ||
| Q3 24 | 2.4% | 2.0% | ||
| Q2 24 | 1.5% | 1.4% | ||
| Q1 24 | 1.4% | 1.4% |
现金转化率AMRXTNET
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | 2.12× | ||
| Q2 25 | 3.74× | 2.03× | ||
| Q1 25 | 0.61× | 1.12× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | 6.62× | 0.65× | ||
| Q1 24 | — | 1.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
TNET
| Insurance Services | $1.1B | 85% |
| Professional Services | $169.0M | 14% |
